Australian Pharmaceutical Company Introduces Erectile Dysfunction Nasal Spray in US
Pecohub Roxus (LTR Pharma Limited), a new nasal spray for erectile dysfunction, is now available in the United States, according to a press release from Mavrox, a men’s health telemedicine platform.
The spray contains vardenafil, a drug used to treat erectile dysfunction, and uses the same nasal formulation as Spontan, LTR Pharma’s nasal spray available by prescription in Australia for the past 2 years, the release said.
A peer-reviewed phase 1 study found that nasal vardenafil reached peak blood levels in a median of 10 minutes, compared with 45-60 minutes for tablets. Men aged 65 or older reached peak levels just as quickly, and the spray achieved peak levels with one quarter of the tablet dose.
Roxus is available by prescription through Mavrox. Patients can complete an online health assessment at Mavrox.com/Roxus to be evaluated for a prescription or ask their healthcare provider about the treatment.
Roxus is a compounded medication that has not been reviewed or approved by the FDA for safety or effectiveness, the release said.
Roxus should not be used with nitrates or riociguat, and it should not be used by by people allergic to vardenafil. Patients should tell their healthcare provider about any heart, liver, or kidney conditions and all medications they take.
Common side effects include headache, flushing, nasal congestion, runny nose, indigestion, and nasal discomfort. Patients should seek emergency medical care for an erection lasting more than 4 hours or sudden vision or hearing loss.
